BG
APLS

Bellevue Group’s Apellis Pharmaceuticals APLS Stock Holding History

Bellevue Group’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-4,210
Closed -$106K – 158
2025
Q4 		$106K Buy
+4,210
New +$98.8K ﹤0.01% 161
2024
Q4 		– Sell
-19,046
Closed -$549K – 162
2024
Q3 		$549K Sell
19,046
-425,358
-96% -$15.8M 0.01% 127
2024
Q2 		$17M Sell
444,404
-29,511
-6% -$1.34M 0.28% 80
2024
Q1 		$27.9M Sell
473,915
-347,885
-42% -$22.2M 0.42% 67
2023
Q4 		$49.2M Buy
821,800
+27,959
+4% +$1.42M 0.75% 43
2023
Q3 		$30.2M Buy
793,841
+275,346
+53% +$12.1M 0.49% 60
2023
Q2 		$47.2M Sell
518,495
-590,887
-53% -$51M 0.67% 50
2023
Q1 		$73.2M Buy
1,109,382
+5,165
+0.5% +$298K 1.06% 31
2022
Q4 		$57.1M Buy
1,104,217
+96,773
+10% +$5.13M 0.76% 40
2022
Q3 		$68.8M Sell
1,007,444
-198,978
-16% -$11.8M 0.99% 36
2022
Q2 		$54.6M Buy
1,206,422
+107,710
+10% +$4.91M 0.77% 43
2022
Q1 		$55.8M Buy
1,098,712
+448,121
+69% +$19.8M 0.65% 53
2021
Q4 		$30.8M Buy
650,591
+602,591
+1,255% +$23.7M 0.32% 85
2021
Q3 		$1.58M Hold
48,000
– – 0.02% 154
2021
Q2 		$3.03M Hold
48,000
– – 0.03% 138
2021
Q1 		$2.06M Hold
48,000
– – 0.02% 142
2020
Q4 		$2.75M Buy
+48,000
New +$2.03M 0.03% 135
2020
Q2 		– Sell
-29,900
Closed -$801K – 209
2020
Q1 		$801K Buy
+29,900
New +$1.06M 0.02% 145

Other funds holding APLS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Bellevue Group's APLS Position: Q1 2026 in Review

Bellevue Group sold out of Apellis Pharmaceuticals (APLS) in Q1 2026, closing a stake of 4,210 shares — an estimated $106K sold.

Bellevue Group first reported a position in APLS in Q1 2020 and held it in 18 quarters. The position peaked at $73.2M in Q1 2023. 323 funds tracked by Wall St. Rank hold APLS as of Q1 2026.

  • Bellevue Group reported no remaining Apellis Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Bellevue Group sold 4,210 Apellis Pharmaceuticals shares in Q1 2026, an estimated $106K.
  • Bellevue Group first reported a position in Apellis Pharmaceuticals in Q1 2020 and held it in 18 quarters.
  • Bellevue Group's Apellis Pharmaceuticals position peaked at $73.2M in Q1 2023.
  • 323 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q1 2026.

Based on Bellevue Group's 13F filing for Q1 2026, filed 15 May 2026.